entertainment -WSS

entertainment

author：entertainment 2025-10-03 00:04:10 - browse：4486

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Lung cancer screening guidelines updated for cigarette smokers

hotspot

WSS

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Brain injuries and the importance of a second opinion

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Bill would allow buprenorphine prescription for addiction via telehealth

STAT wants to know your pick for a great summer read or listen

The health care issue Democrats can’t solve: hospital reform

entertainment

entertainment

entertainment

Medicare details structure of new drug price negotiation program

ASCO Daily Recap: CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Gene therapy’s promise and the high cost of hope

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Psychedelics group wrestles with new pharma identity

Medicare Advantage's lean provider networks lead CMS complaints

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Brain injuries and the importance of a second opinion

Wikipedia

Data don't support strong claims for Covid

Medicare must police algorithms in Medicare Advantage, Dems say

CMS got Medicare Advantage quality rating wrong, judge rules

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Medicare proceeds with plan to claw back hospital funds

Medicare must police algorithms in Medicare Advantage, Dems say

Wikipedia

hotspot

Wikipedia

explore